Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
CytoDyn and Natera announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics in CytoDyn’s CLOVER Phase 2 study for metastatic colorectal cancer. Natera will use its Signatera assay to analyze clinical trial samples and provide real-world data insights from its proprietary oncology database, which contains over 2 million plasma timepoints.
Key figures
- Natera dataset size
- 2 million plasma timepoints
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.